Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ZBIO
Upturn stock ratingUpturn stock rating

Zenas BioPharma, Inc. Common Stock (ZBIO)

Upturn stock ratingUpturn stock rating
$16.76
Last Close (24-hour delay)
Profit since last BUY20.65%
upturn advisory
SELL
SELL since 4 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: ZBIO (1-star) is a SELL. SELL since 4 days. Profits (20.65%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $32.14

1 Year Target Price $32.14

Analysts Price Target For last 52 week
$32.14 Target price
52w Low $5.83
Current$16.76
52w High $26.25

Analysis of Past Performance

Type Stock
Historic Profit -36.37%
Avg. Invested days 25
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 460.59M USD
Price to earnings Ratio -
1Y Target Price 32.14
Price to earnings Ratio -
1Y Target Price 32.14
Volume (30-day avg) 7
Beta -
52 Weeks Range 5.83 - 26.25
Updated Date 05/20/2025
52 Weeks Range 5.83 - 26.25
Updated Date 05/20/2025
Dividends yield (FY) -
Basic EPS (TTM) -11.89

Earnings Date

Report Date 2025-08-12
When Before Market
Estimate -1.06
Actual -1.25

Profitability

Profit Margin -
Operating Margin (TTM) -373.3%

Management Effectiveness

Return on Assets (TTM) -56.7%
Return on Equity (TTM) -115.47%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 110831343
Price to Sales(TTM) 30.71
Enterprise Value 110831343
Price to Sales(TTM) 30.71
Enterprise Value to Revenue 22.17
Enterprise Value to EBITDA -
Shares Outstanding 41834200
Shares Floating 20950558
Shares Outstanding 41834200
Shares Floating 20950558
Percent Insiders 21.2
Percent Institutions 74.81

ai summary icon Upturn AI SWOT

Zenas BioPharma, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of therapies for patients suffering from autoimmune diseases. They focus on innovative immunotherapies.

business area logo Core Business Areas

  • Immunotherapy Development: Focuses on discovering and developing novel immunotherapies for autoimmune diseases.
  • Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
  • Commercialization: Commercializes approved therapies globally.

leadership logo Leadership and Structure

The leadership team comprises experienced executives with expertise in drug development, commercialization, and corporate strategy. The organizational structure is typical of a biopharmaceutical company, with departments focusing on research, development, clinical trials, regulatory affairs, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • Obexelimab: Obexelimab is a potential treatment being developed for autoimmune diseases. Specific market share data, user numbers, and revenue figures are not currently publicly available. Competitors include companies developing similar therapies, such as those targeting B cells or other immune pathways. These might include therapies targeting CD20 (rituximab).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and rapidly evolving, with significant investment in research and development. The autoimmune disease market is a large and growing segment, driven by an aging population and increased awareness of autoimmune disorders.

Positioning

Zenas BioPharma is positioning itself as a leader in the development of novel immunotherapies for autoimmune diseases. Their focus on specific targets and mechanisms of action differentiates them from some competitors.

Total Addressable Market (TAM)

The TAM for autoimmune disease therapies is estimated to be in the tens of billions of dollars. Zenas BioPharma aims to capture a significant portion of this market with its innovative pipeline.

Upturn SWOT Analysis

Strengths

  • Innovative immunotherapy pipeline
  • Experienced leadership team
  • Focus on unmet medical needs
  • Strong research and development capabilities

Weaknesses

  • Reliance on clinical trial success
  • High research and development costs
  • Dependence on regulatory approvals
  • Limited commercialized products

Opportunities

  • Expansion into new autoimmune indications
  • Partnerships with larger pharmaceutical companies
  • Acquisition of complementary technologies
  • Accelerated regulatory pathways

Threats

  • Competition from established pharmaceutical companies
  • Clinical trial failures
  • Regulatory hurdles
  • Patent expirations

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • BMY
  • ABBV
  • JNJ

Competitive Landscape

Zenas BioPharma competes with large, established pharmaceutical companies and other smaller biotech firms developing autoimmune therapies. Their success depends on the differentiation and efficacy of their drug candidates.

Growth Trajectory and Initiatives

Historical Growth: Historical growth would be reflected in the expansion of the pipeline and progress in clinical trials.

Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization efforts.

Recent Initiatives: Recent initiatives could include new clinical trial starts, partnerships, and fundraising activities.

Summary

Zenas BioPharma is a clinical-stage biopharmaceutical company focusing on autoimmune disease therapies and has an innovative pipeline, though it faces risks with clinical trials. Being a small cap, Zenas BioPharma depends on future clinical trial success to deliver on their goals. They must efficiently manage resources and successfully navigate regulatory hurdles. Competition from larger companies presents a significant challenge.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports
  • Analyst Reports

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share is estimated and may not be precise. Data is current as of October 26, 2023.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Zenas BioPharma, Inc. Common Stock

Exchange NASDAQ
Headquaters Waltham, MA, United States
IPO Launch date 2024-09-13
CEO & Chairman of the Board Mr. Leon Oliver Moulder Jr., M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 130
Full time employees 130

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.